IPO
AimedBio Co., Ltd.
에임드바이오
Stock page →What the company does
Develops antibody-drug conjugate (ADC) cancer drugs based on patient-derived models, and has licensed candidates to global pharmaceutical partners. Spun off from Samsung Seoul Hospital.
Themes:Biotech (new drugs)
- Market
- KOSDAQ
- Price range
- Not set yet
- Offer price
- ₩11,000
- Subscription
- Not set yet
- Payment date
- Not set yet
- Listing
- Dec 4, 2025
- First day
- ▲ +300.0% ₩44,000
- First close vs the offer price
Filings
- [기재정정]투자설명서Nov 20, 2025Open on DART ↗
- [발행조건확정]증권신고서(지분증권)Nov 20, 2025Open on DART ↗
- 투자설명서Nov 18, 2025Open on DART ↗
- [기재정정]증권신고서(지분증권)Nov 17, 2025Open on DART ↗
- [기재정정]증권신고서(지분증권)Nov 10, 2025Open on DART ↗
- [기재정정]증권신고서(지분증권)Oct 27, 2025Open on DART ↗
How a Korean IPO works: institutions bid first (the demand forecast), which sets the final offer price; then individuals subscribe for two days through the lead managers' brokerage accounts; shares start trading on the listing date.
Dates and prices can change until the final terms are filed. Not financial advice. · Updated Oct 17, 2026 · IPO calendar